AE	Adverse event
AJCC	American Joint Committee on Cancer
CI	Confidence interval
CR	Complete response
CTCAE	Common Terminology Criteria for Adverse Events
CTLA-4	Cytotoxic T-lymphocyte–associated protein 4
DEC-C	Decitabine/cedazuridine
DLT	Dose-limiting toxicity
DNA	Deoxyribonucleic acid
DNMT1	DNA methyltransferase 1
ECOG	Eastern Cooperative Oncology Group
EOT	End of treatment
FDA	United States Food and Drug Administration
GAPDH	Glyceraldehyde-3-phosphate dehydrogenase
gDNA	Genomic DNA
GZMB	Granzyme B
HMA	Hypomethylating agent
ICI	Immune checkpoint inhibitor
IFI6	Interferon alpha-inducible protein 6
IFI27	Interferon alpha-inducible protein 27
IFI44L	Interferon-induced protein 44-like
IFN	Interferon
IIPS	Innate immune pathogen-sensing
IL	Interleukin
IQR	Interquartile range
LAG-3	Lymphocyte-activation gene 3
LDH	Lactate dehydrogenase
LINE-1	Long interspersed nuclear element-1
M:U	Methylated-to-unmethylated
MDSC	Myeloid-derived suppressor cell
MHC	Major histocompatibility complex
MTD	Maximum tolerated dose
NCCN	National Comprehensive Cancer Network
NK	Natural killer
NKG2D	Natural killer group 2 member D
NR	Not reached
ORR	Objective response rate
OS	Overall survival
PBMC	Peripheral blood mononuclear cell
PD	Progressive disease
PD-1	Programmed death-1
PFS	Progression-free survival
PR	Partial response
qRT-PCR	Quantitative real-time polymerase chain reaction
RECIST	Response Evaluation Criteria in Solid Tumors
RIG-I	Retinoic acid-inducible gene-I
RNA	Ribonucleic acid
RP2D	Recommended phase II dose
SAE	Serious adverse event
SD	Stable disease
SEM	Standard error of the mean
TIM-3	T-cell immunoglobulin and mucin-domain containing-3
TITE-BOIN	Time-to-event Bayesian optimal interval
TNF-α	Tumor necrosis factor-alpha
Treg	Regulatory T cell
ULN	Upper limit of normal